Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYH2051 + SYS6010 in Advanced GI Tumors
NCT07104877Phase 1Active, not recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Apr 2024
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CPO301 and SYH2051 in colorectal cancer (CRC), gastric cancer (GC) and gastrointestinal tumor, sponsored by Fujian Medical University Cancer Hospital. Primary endpoints: Adverse Event (AE) and Dose-limiting toxicities up to 21 days. Started Apr 2024; status: active, not recruiting.
02
Drugs
CPO301SYH2051
03
Conditions
colorectal cancer (CRC)gastric cancer (GC)gastrointestinal tumor
Beyond the preview
Go deeper on NCT07104877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07104877.